early detection

Both the MRD test, BR Prophet, and a six-cancer screening assay, BR Predict, are slated for launch in China next year, initially for contracted hospital customers.

Based on promising early results, the company is now conducting a larger case-control study to lock in a classifier for prospective validation in an intended-use population.

Illumina said it will hold Grail as a separate company during the European Commission's ongoing regulatory review and abide by the outcome of the FTC's administrative trial.